Published date: 31 May 2019

Awarded contract - This means that the contract has been awarded to a supplier.


Closing: 26 May 2019

Contract summary

Industry

  • Reagents and contrast media - 33696000

Location of contract

London

Value of contract

£1,500,000 to £2,000,000

Procurement reference

CHELWEST-DN403487-13862453

Published date

31 May 2019

Closing date

26 May 2019

Contract start date

1 June 2019

Contract end date

30 May 2021

Contract type

Supply contract

Procedure type

Other

Contract is suitable for SMEs?

No

Contract is suitable for VCSEs?

No

Description

The Royal Marsden Hospital requires purchase of ANMI PSMA Setrile 360 VIALS and ANMI Elution Tools Gen A to treat prostate cancer.
ANMI PSMA Setrile 360 Vials and ANMI Elution Tools Gen A is the only viable kit for imaging of prostate cancer in UK
PMSA-11 is the most specific peptide-chelator available for diagnosis of prostate cancer.
No other available treatment as effective are available on the NHS - Ga-68 PSMA scan can be used in PET imaging. PET imaging provides greater resolution and speed of imaging and therefore diagnosis of prostate cancer.
PSMA (Prostate Specific Membrane Antigens) are over expressed on Prostate Tumours and therefore, by targeting and Imaging them with Radiopharmaceutical compounds, enables clinicians to better diagnose and manage patient's recurrent prostate cancer disease.
There is currently no Marketing Authorisation for this product.
The HBEDCC-11 kit Peptide, from ANMI, is the most widely available and popular choice at this time, that efficiently labels with Ga68 and provides high quality and accurate diagnosis of Prostate PSMA.
The Royal Marsden Radiopharmacy already operates an efficient Ga68 Generator and therefore, is capable of combining with this HBEDCC-11 peptide from ANMI.
Use of Ga-68 generator enables production of Ga-68 PSMA on-site allowing flexibility of service and negates reliance on outsourced companies for delivery radiopharmaceuticlals
Curium is the official UK Distributor of the ANMI HBEDCC-11 PSMA Kit and follows the Regulated Import Pathway approved by the MHRA for this product.

Award information

Awarded date

31 May 2019

Contract start date

1 June 2019

Contract end date

30 May 2021

Total value of contract

£2,200,000

This contract was awarded to 1 supplier.

Curium Pharma UK Ltd,

Address

Suite G30, Regus, 1000 Lakeside, Western Road, Portsmouth, Hampshire, United Kingdom PO6 3EZ

Reference

None

Supplier is SME?

No

Supplier is VCSE?

No

About the buyer

Address

Unit G3
Harbour Yard, Chelsea Harbour
London
SW10 0XD
England

Email

tenders@chelwest.nhs.uk